Skip to main content
. Author manuscript; available in PMC: 2008 Nov 1.
Published in final edited form as: J Pain. 2007 Jul 23;8(11):850–860. doi: 10.1016/j.jpain.2007.05.015

Table 2.

Anti-Improgan activity vs. CB1 activity.

Drug Active Dose (icv, nmol) % Inhbition of Imp Rel. Active Dose (/SR) CB1 Kd (nM) Rel. CB1 Kd (/SR)
Rimonabant 43 48 1.0 0.23 1.00
O-1691 25 70 0.6 0.22 0.96
O-1876 300 65 7.0 139 604
O-848 30 50 0.7 352 1,530

For each drug, the dose and degree of inhibition of improgan antinociception is given. Relative active dose refers to the quotient of the active dose of the specified drug divided by the active dose of rimonabant (43 nmol). CB1 Kd values were calculated from Schild plots (Fig. 7F). Relative CB1 Kd refers to the quotient of the calculated CB1 Kd of the drug divided by the calculated CB1 Kd of rimonabant (0.23 nM). All percent inhibition values were calculated using 10 minute post improgan injection data.